Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial.

Sellas Life Sciences Group, Inc. declined 1.58% in premarket trading. The company recently met primary endpoints in mid-stage trials for its product candidates, galinpepimut-S (GPS) and SLS009, showing promising results in treating various cancer indications. The FDA has recommended advancing towards a trial including newly diagnosed first-line AML patient cohorts, which may support a New Drug Application.